Literature DB >> 30161038

Alcohol and Drug Overdose and the Influence of Pain Conditions in an Addiction Treatment Sample.

Anne C Fernandez1, Christopher Bush, Erin E Bonar, Frederic C Blow, Maureen A Walton, Amy S B Bohnert.   

Abstract

PURPOSE: Overdose from alcohol and/or drugs kills tens of thousands of Americans annually, with a large number of deaths attributed to opioid pain medications. Addiction treatment patients are known to be at high risk for overdose; however, the relationship between pain and overdose history within this group is understudied, especially in relation to alcohol overdoses. In the present study, we evaluated whether nonfatal overdose history was more likely among addiction treatment patients with pain, and examined the characteristics of overdoses among those with and without pain.
METHODS: We analyzed cross-sectional data from 739 patients at a large residential addiction treatment center (median age 37, 25.7% female). We used 2-stepped binary regression models to evaluate whether demographics, pain type (chronic, acute, or both), depression symptoms, and opioid misuse were associated with lifetime history of nonfatal (1) alcohol and (2) drug overdose (lifetime yes/no), and conducted follow-up analyses examining overdose characteristics.
RESULTS: In adjusted analyses, history of chronic pain (odds ratio [OR] 2.60, 95% confidence interval [CI] 1.59, 4.27) and illicit drug use (OR 1.99, 95% CI 1.07, 3.68) were associated with an increased likelihood of nonfatal alcohol overdose. Opioid misuse (OR 3.11, 95% CI 2.51, 3.86), depression symptoms (OR 1.33, 95% CI 1.14, 1.55), and younger age (OR 0.96, 95% CI 0.94, 0.97) were associated with increased likelihood of drug overdose. Those with pain reported a higher number of lifetime alcohol overdoses and were more likely to combine numerous drugs with alcohol before overdose.
CONCLUSIONS: Pain conditions may play an under-recognized role in the overdose epidemic, particularly alcohol-related overdose. Addiction treatment and overdose prevention interventions should incorporate appropriate assessment and treatment of pain including education about the risks of polysubstance use, particularly combining alcohol with sedatives and prescription pain relievers.

Entities:  

Mesh:

Year:  2019        PMID: 30161038      PMCID: PMC6533535          DOI: 10.1097/ADM.0000000000000451

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  28 in total

Review 1.  Alcohol and Opioid Use, Co-Use, and Chronic Pain in the Context of the Opioid Epidemic: A Critical Review.

Authors:  Katie Witkiewitz; Kevin E Vowles
Journal:  Alcohol Clin Exp Res       Date:  2018-02-06       Impact factor: 3.455

2.  [Commentary]Can one be an expert in addiction medicine without expertise in pain management?

Authors:  Jeffrey H Samet; Alexander Y Walley
Journal:  Addiction       Date:  2008-12       Impact factor: 6.526

3.  A randomized trial of a pain management intervention for adults receiving substance use disorder treatment.

Authors:  Mark A Ilgen; Amy S B Bohnert; Stephen Chermack; Carly Conran; Mary Jannausch; Jodie Trafton; Frederic C Blow
Journal:  Addiction       Date:  2016-04-15       Impact factor: 6.526

4.  Physical Pain in Alcohol-Dependent Patients Entering Treatment in Poland—Prevalence and Correlates.

Authors:  Andrzej Jakubczyk; Mark A Ilgen; Amy S B Bohnert; Maciej Kopera; Aleksandra Krasowska; Anna Klimkiewicz; Frederic C Blow; Kirk J Brower; Marcin Wojnar
Journal:  J Stud Alcohol Drugs       Date:  2015-07       Impact factor: 2.582

5.  Treatment needs associated with pain in substance use disorder patients: implications for concurrent treatment.

Authors:  Jodie A Trafton; Elizabeth M Oliva; Doyanne A Horst; Jared D Minkel; Keith Humphreys
Journal:  Drug Alcohol Depend       Date:  2004-01-07       Impact factor: 4.492

6.  The association of persistent pain with out-patient addiction treatment outcomes and service utilization.

Authors:  Ryan M Caldeiro; Carol A Malte; Donald A Calsyn; John S Baer; Paul Nichol; Daniel R Kivlahan; Andrew J Saxon
Journal:  Addiction       Date:  2008-10-08       Impact factor: 6.526

7.  An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index.

Authors:  A T McLellan; L Luborsky; G E Woody; C P O'Brien
Journal:  J Nerv Ment Dis       Date:  1980-01       Impact factor: 2.254

8.  Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths - United States, 2010.

Authors:  Christopher M Jones; Leonard J Paulozzi; Karin A Mack
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-10-10       Impact factor: 17.586

9.  A pilot randomized clinical trial of an intervention to reduce overdose risk behaviors among emergency department patients at risk for prescription opioid overdose.

Authors:  Amy S B Bohnert; Erin E Bonar; Rebecca Cunningham; Mark K Greenwald; Laura Thomas; Stephen Chermack; Frederic C Blow; Maureen Walton
Journal:  Drug Alcohol Depend       Date:  2016-03-26       Impact factor: 4.492

10.  Preliminary validation of the Michigan Body Map.

Authors:  Chad M Brummett; Rishi R Bakshi; Jenna Goesling; Daniel Leung; Stephanie E Moser; Jennifer W Zollars; David A Williams; Daniel J Clauw; Afton L Hassett
Journal:  Pain       Date:  2016-06       Impact factor: 7.926

View more
  8 in total

1.  Validation and threshold identification of a prescription drug monitoring program clinical opioid risk metric with the WHO alcohol, smoking, and substance involvement screening test.

Authors:  Gerald Cochran; Jennifer Brown; Ziji Yu; Stacey Frede; M Aryana Bryan; Andrew Ferguson; Nadia Bayyari; Brooke Taylor; Margie E Snyder; Elizabeth Charron; Omolola A Adeoye-Olatunde; Udi E Ghitza; T Winhusen
Journal:  Drug Alcohol Depend       Date:  2021-09-24       Impact factor: 4.492

2.  Associations between elevated depressive symptoms and substance use, prescription opioid misuse, overdose history, pain, and general health among community pharmacy patients prescribed opioids.

Authors:  Jennifer L Brown; Gerald Cochran; M Aryana Bryan; Elizabeth Charron; T John Winhusen
Journal:  Subst Abus       Date:  2022       Impact factor: 3.984

3.  Risky alcohol use among patients dispensed opioid medications: A clinical community pharmacy study.

Authors:  Gerald Cochran; Elizabeth Charron; Jennifer L Brown; Alina Cernasev; Kenneth C Hohmeier; T John Winhusen
Journal:  Drug Alcohol Depend       Date:  2022-03-16       Impact factor: 4.852

4.  Pain Severity and Interference and Substance Use Among Community Pharmacy Patients Prescribed Opioids: A Secondary Analysis of the PHARMSCREEN Study.

Authors:  Elizabeth Charron; Akiko Okifuji; M Aryana Bryan; Sarah Reese; Jennifer L Brown; Andrew Ferguson; Udi E Ghitza; T Winhusen; Gerald Cochran
Journal:  J Pain       Date:  2022-04-11       Impact factor: 5.383

5.  Justice involvement patterns, overdose experiences, and naloxone knowledge among men and women in criminal justice diversion addiction treatment.

Authors:  Rachel E Gicquelais; Briana Mezuk; Betsy Foxman; Laura Thomas; Amy S B Bohnert
Journal:  Harm Reduct J       Date:  2019-07-16

6.  Mindfulness-Oriented Recovery Enhancement for Addictive Behavior, Psychiatric Distress, and Chronic Pain: A Multilevel Meta-Analysis of Randomized Controlled Trials.

Authors:  Anna Parisi; R Lynae Roberts; Adam W Hanley; Eric L Garland
Journal:  Mindfulness (N Y)       Date:  2022-09-15

7.  Opportunities to boost naloxone awareness among people who misuse opioid analgesics who have not used illegal opioids.

Authors:  Rachel E Gicquelais; Amy S B Bohnert; Anne C Fernandez
Journal:  Subst Abus       Date:  2020-07-21       Impact factor: 3.716

8.  A comprehensive multivariate model of biopsychosocial factors associated with opioid misuse and use disorder in a 2017-2018 United States national survey.

Authors:  Francisco A Montiel Ishino; Philip R McNab; Tamika Gilreath; Bonita Salmeron; Faustine Williams
Journal:  BMC Public Health       Date:  2020-11-18       Impact factor: 3.295

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.